PRP is under clinical development by Propanc Biopharma and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRP overview

PRP is under development for the treatment of solid tumors such as pancreatic, ovarian cancer, melanoma, colorectal cancer, gastric, prostate, Non-Hodgkin Lymphoma, Mesothelioma, Neuro-endocrine tumor, NSCLC, gastrointestinal cancer such as bowel, abdomen cancer, colon, breast, small-cell carcinoma, renal and bladder. . The drug candidate is administered through intravenous, intratumoral injection and rectal route as suppository. It is a formulation of proteolytic proenzymes comprising amylase and the proenzymes of trypsinogen and chymotrypsinogen. PRP activates E-Cadherin and beta-Catenin expression.

Propanc Biopharma overview

Propanc Biopharma is a clinical stage biopharmaceutical company, which manufactures products for the treatment of metastatic, pancreatic, ovarian and colorectal cancers. The company’s lead product candidate, PRP, a once-a-day intravenous formulation of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, helps block the recurrence of tumor and metastasis. PRP curtails tumor growth by curbing cancer cell migration and suppressing tumor blood vessel formation, and ultimately causing cell death. Its pipeline products PRP is in preclinical stage and POP1 is in research stage. The company has its operations in Australia and the US. Propanc Biopharma is headquartered in Melbourne, Victoria, Australia.

For a complete picture of PRP’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.